Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial
- SOLID-TIMI 52 Investigators
- Brigham and Women's Hospital
- Auckland City Hospital
- Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, Philadelphia, Pennsylvania.
- Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania.
- AP-HP Assistance Publique - Hopitaux de Paris
- Department of Medicine, NYU Langone Medical Center, New York.
- University of Freiburg
- ANMCO Research Center, Florence, Italy.
- Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, Research Triangle Park, North Carolina.
- Henry Ford Heart and Vascular Institute, Detroit, Michigan.
- Erasmus University Medical Center
416
Link opens in a new tab
Citations
(Scopus)